Health | WPN World People News

An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the United States from infection for more than one year after immunization, according to results from a Phase 1 trial described in the May 9th issue of Nature Medicine. The vaccine, known as the PfSPZ Vaccine, was developed and produced by Sanaria Inc., of Rockville, Maryland, with support from several Small Business Innovation Research (SBIR) awards from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Mother breasfteeding her baby in Bangladesh, 2015. Bangladesh has cut its child mortality rates by roughly half in recent decades.

We saw a doubling of the number of people on lifesaving HIV treatment over the last five years in order to exceed the global commitment of reaching 15 million people with treatment by 2015. The number of people on treatment will need to double again in the next five years to reach the new goal of 30 million people on HIV treatment by 2020. Every day, we need to see more people starting HIV treatment than the day before if the world wants to get ahead of the wave with this epidemic.

Through the use of powerful genomic techniques, researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have found that the development of immune cells, called innate lymphoid cells (ILCs), gradually prepares these cells for rapid response to infection. This work, sheds light on the development and function of a cell type that is increasingly recognized as having an important role in the body’s immune defense. NIAMS is part of the National Institutes of Health.

In Dinajpur, Bangladesh, Selina Akter, second year midwifery student, plays the role of a mother as students practice postnatal care at the Dinajpur nursing institute.